An infusion or injection solution of Levodopa containing at least 10 mg/mL ofLevodopa, or at least 5 mg/mL of Levodopa together with at least 0.5 mg/mL ofat least one inhibitor of a Levodopa-metabolising enzyme is disclosed. Thesolution further contains a buffer, a physiologically acceptable sugar, suchas glucose, a physiologically acceptable acid, such as hydrochloric acid, andoptionally a stabilizer, and has a pH of lower than or equal to 6. There arealso described a disposable syringe containing an infusion or injectionsolution of Levodopa, optionally together with a Levodopa-metabolising enzyme,and an infusion pumpcassette containing an infusion or injection solution ofLevodopa optionally together with a Levodopa-metabolising enzyme.
